Recombivax HB (Hepatitis B Vaccine (Recombinant)) - Summary

RECOMBIVAX HB SUMMARY

RECOMBIVAX HB Hepatitis B Vaccine (Recombinant) is a non-infectious subunit viral vaccine derived from Hepatitis B surface antigen (HBsAg) produced in yeast cells. A portion of the hepatitis B virus gene, coding for HBsAg, is cloned into yeast, and the vaccine for hepatitis B is produced from cultures of this recombinant yeast strain according to methods developed in the Merck Research Laboratories.

RECOMBIVAX HB is indicated for vaccination against infection caused by all known subtypes of hepatitis B virus. RECOMBIVAX HB Dialysis Formulation is indicated for vaccination of adult predialysis and dialysis patients against infection caused by all known subtypes of hepatitis B virus.

RECOMBIVAX HB NEWS HIGHLIGHTS

Media Articles Related to Recombivax HB (Hepatitis B Vaccine)

Hepatitis B Vaccine Not Associated with Multiple Sclerosis
Source: MedPage Today Neurology [2008.09.26]

Start Of "Influenza Season": Severity Of This Winter's Epidemic Not Yet Clear But ECDC Supports Vaccination Of Risk Groups
Source: Respiratory / Asthma News From Medical News Today [2008.10.09]

National Pharmacy Association Highlights Community Pharmacy Contribution To Flu Vaccination, UK
Source: Flu / Cold / SARS News From Medical News Today [2008.10.07]

Pregnant Women Reminded To Get Flu Vaccination
Source: Flu / Cold / SARS News From Medical News Today [2008.10.05]

Scotland's Doctors Encourage Patients To Get Their Flu Vaccination
Source: Flu / Cold / SARS News From Medical News Today [2008.10.01]

more>>

Published Studies Related to Recombivax HB (Hepatitis B Vaccine)

A non-randomized vaccine effectiveness trial of accelerated infant hepatitis B immunization schedules with a first dose at birth or age 6 weeks in Cote d'Ivoire. [2008.05.23]

The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components. [2008.05]

CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. [2008.04.15]

A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. [2008.04]

Long-term antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents. [2008.03.25]

more>>

Clinical Trials Related to Recombivax HB (Hepatitis B Vaccine)

Effectiveness of Two Hepatitis B Vaccines in HIV-Negative Youths [Active, not recruiting]

Immunologic Memory (Supp. of ATN 024) [Completed]

more>>